Candel Therapeutics Inc (CADL) USD0.01

Sell:$4.76Buy:$4.98$0.18 (3.85%)

Prices delayed by at least 15 minutes
Sell:$4.76
Buy:$4.98
Change:$0.18 (3.85%)
Prices delayed by at least 15 minutes
Sell:$4.76
Buy:$4.98
Change:$0.18 (3.85%)
Prices delayed by at least 15 minutes

Company Information

About this company

Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.

Key people

Paul Peter Tak
President, Chief Executive Officer, Director
Charles Schoch
Chief Financial Officer
Francesca Barone
Chief Scientific Officer
W. Garrett Nichols
Chief Medical Officer
Seshu Tyagarajan
Chief Technical and Development Officer
Paul B. Manning
Independent Chairman of the Board
Edward J. Benz
Independent Director
Renee M. Gaeta
Independent Director
Nicoletta Loggia
Independent Director
Christopher Martell
Independent Director
Click to see more

Key facts

  • EPIC
    CADL
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US1374041093
  • Market cap
    $233.98m
  • Employees
    38
  • Shares in issue
    50.23m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.